Idarucizumab - Boehringer Ingelheim

Drug Profile

Idarucizumab - Boehringer Ingelheim

Alternative Names: BI-655075; Praxbind

Latest Information Update: 12 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Boehringer Ingelheim
  • Class Antidotes; Coagulants; Fab fragments; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Blood coagulation disorders
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Blood coagulation disorders

Most Recent Events

  • 12 Sep 2017 Boehringer Ingelheim completes a phase-I clinical trials in Coagulation disorders (In volunteers) in China (IV) (NCT03086356)
  • 11 Jul 2017 Final efficacy and adverse events data from the phase III RE-VERSE AD™ trial in Coagulation disorders released by Boehringer Ingelheim
  • 10 May 2017 Phase-I clinical trials in Coagulation disorders (In volunteers) in China (IV) (NCT03086356)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top